Bioreducible PEI-siRNA Nanocomplex for Liver Cancer Therapy: Transfection, Biodistribution, and Tumor Growth Inhibition In Vivo
Figure 3
SS-PEI-mediated GFP-siRNA transfection in SGC-7901 cells stably expressing GFP gene and VEGF-siRNA transfection in HepG2 cells in vitro. GFP gene expression (a) and cell viability (b) of SGC-7901 cells after siRNA transfection with SS-PEI/GFP-siRNA at different N/P ratios; (c) The expression of VEGF in HepG2 cells after siRNA transfection with SS-PEI/siRNA complexes at an optimal N/P ratio. Lipofectamine 2000 is used as a positive control; (d) Flow cytometry histogram of HepG2 cells treated with SS-PEI/FAM-siRNA; (e) Fluorescent microscopic images of HepG2 cells treated with SS-PEI/FAM-siRNA. (Scale bar: 50 μm).
